Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVERLAST-B: ORKA-001 in Moderate-to-Severe Plaque Psoriasis
NCT07290569Phase 2Active, not recruiting
- Sponsor
- Oruka Therapeutics
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of orka-001 in plaque psoriasis, sponsored by Oruka Therapeutics. Started Dec 2025; status: active, not recruiting.
02
Drugs
orka-001
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07290569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290569.